VoxNeuro

VoxNeuro provides a comprehensive cognitive health assessment that integrates neuropsychological and cognitive tests with EEG-based brain performance software to deliver objective scores of cognitive function. The assessment process is non-invasive and rapid, utilizing EEG-based cognitive biomarkers to measure attention, concentration, information processing, and memory. Quantitative measures are evaluated against a normative database validated across age and sex cohorts from 12 to 90 years old. The assessment is applicable to over 20 clinical conditions, including concussion, schizophrenia, traumatic brain injury, major depressive disorder, neurodegenerative diseases, ADHD, and mild cognitive impairment. VoxNeuro CORE is reimbursable with established medical necessity and uses standard EEG equipment with a minimum number of electrodes, which can be stationary or portable. Training is provided for office staff, and the assessment does not require EEG technicians or neuropsychologists to administer. Cloud-based software instantly generates patient reports, and the assessment includes various tests such as the Awake and Drowsy Test, Auditory Evoked Potential Test, Visual Evoked Potential Test, Attention and Concentration & Information Processing Test, and Memory Test. The company holds U.S. Patent No. 11,278,230 for systems and methods for cognitive health assessment and is registered with the FDA and Health Canada, making it available for use in clinical settings in the US and Canada. VoxNeuro’s Cognitive Health Assessment Management Platform (CHAMP) is a software device that uses neurophysiological output values from cognitive tasks to interpret cognitive function and is indicated as an adjunctive tool for evaluating cognitive function in individuals aged 12-90. VoxNeuro’s practices comply with the Personal Health Information Protection Act (PHIPA) in Canada and the Health Insurance Portability and Accountability Act (HIPAA) in the US.